Alterity Therapeutics Ltd. (AU:ATH) has released an update.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Alterity Therapeutics Ltd., a biotech firm focusing on neurodegenerative disease treatments, will feature in a fireside chat at the 2024 Maxim Healthcare Virtual Summit on October 17th. The company’s CEO, David Stamler, M.D., will represent Alterity, which is currently advancing its lead drug candidate, ATH434, through Phase 2 clinical trials for Multiple System Atrophy. Interested parties can access the webcast live or via a three-month archive on Alterity’s website.
For further insights into AU:ATH stock, check out TipRanks’ Stock Analysis page.
